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ﬁbrillation(NVAF) and further to provide the suggests for choosing reasonable ther-
apeutic schedule of these patients.
Methods: A total of 319 very elderly patients with nonvalvular atrial ﬁbrillation in
eight Department of Grade III hospitals was enrolled during May 2012 to
September 2013. The status of antithrombotic treatment was observed and a
follow-up of three to six months was given. The patients were divided into warfarin
group, antiplatelet group (aspirin or clopidogrel), dual antiplatelet group, warfarin
combined with antiplatelet group, new oral anticoagulants group (dabigatran) and
no antithrombotic group. Inﬂuential factors of antithrombotic treatment, main
terminal events (including bleeding, ischemic events and death) and its affecting
factors were analyzed.
Results: There were 192 men (60.20%) and 127 women (39.80%) involved in the
study and the average age was (84.663.54) years old. 41 patients used warfarin
anticoagulant therapy alone, 158 patients used antiplatelet therapy (aspirin or clo-
pidogrel) alone, 24 used dual antiplatelet, 7 patients used warfarin combined with
aspirin therapy, 7 patients used new oral anticoagulants therapy and 82 patients
were without any of antithrombotic therapies. According to CHADS2 index, there
were 314 patients suggested to use warfarin and the real percentage of using
warfarin was 15.29 %( 48/314). Of the total patients receiving warfarin, the ratio of
monitoring the international normalized ratio (INR) was 79.17 %( 38/48). The
average level of INR was (1.850.53).And patients’ INR between 1.6-2.5 were only
22 cases (57.89%). During the follow-up visits, 319 very elderly patients were
observed. The main terminal events were 90 cases (28.21%), while the bleeding,
ischemic events and death are 26(8.15%), 23 (7.21%) and 41 (12.85%) respectively.
The bleeding and ischemic events of the antithrombotic group is 2 (3.64%) and 3
(5.45%).
Conclusions: Warfarin is underused in very elderly patients with NVAF who had
indications of anticoagulation. And the ratio of targeted INR is not enough. The main
cause of non-anticoagulation. Is worring about bleeding. The antithrombotic group has
lower rate of bleeding and ischemic events. Therefore, the assessment of the risk of
thromboembolism in very elderly patients and the management of anticoagulant
therapy should be strengthened.
GW25-e4595
Clinical efﬁcacy of pitavastatin in treating hypercholesterolemia combined with
chronic heart failure in 24 cases
Zhang Zhao, Cao Xuebin
Department of cardiovascular, Baoding 252 hospital, Baoding, Hebei
Objectives: Pitavastatin is the most reccardiovasculartly approved statin which is
regarded as “superstatins”. This clinical trial was designed to investigate the efﬁcacy
of pitavastatin in treating hypercholesterolemia combined with chronic heart failure.
Methods: Forty-nine patients with hypercholesterolemia combined with chronic heart
failure were divided into the two groups randomly by the blind random method. The
observation group (24 patients) received pitavastatin while the control group (25pa-
tients) received atorvastatin. Both of the two groups received basic therapy of chronic
heart failure including digoxin, Katlex and spironolactone. After a 8-week treatment,
the total cholesterol(TC), low density lipoprotein cholesterol(LDL-C), triglycer-
ides(TG), high density lipoprotein cholesterol(HDL-C) were compared between the
two group.
Results: After treatment the decrease degree of TC and LDL-C in the two groups had
statistical differences (P<0.05).However, TG and HDL-C had no statistical differ-
ences (P>0.05). The reaching standard rate of the LDL-C level and the occurrence
rates of adverse reaction in the two groups had no statistical differences (P>0.05).
Conclusions: Pitavastatin has signiﬁcant effect in treating hypercholesterolemia
combined with chronic heart failure, which can reduce the TC, LDL-C levels, with
low rate of occurrence of adverse reactions. The effect of pitavastatin on the
improvement of chronic heart failure needs more investigation.
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Efﬁcacy and Safety of Varenicline for Smoking Cessation in Patients with CAD
undergoing PCI
Wei Yujie, Liu Huliang
Department of Cardiology, General Hospital of Chinese People’s Armed Police
Forces
Objectives: This study focued on the efﬁcacy of varenicline and the safety of the
combination of two drugs by investigating the patients who were given clopidogrel
and varenicline with CAD undergoing PCI.
Methods: Eligible smoking patients in hospital, with CAD undergoing PCI were
consecutively included. All patients received aspirin (100 mg/day) and clopidogrel
(loading dose 300mg, followed by 75 mg/day). On 3 day after received clopidogrel
75mg/day, patients will be randomized to receive either associated varenicline or
without varenicline for 14 days. Blood samples will be collected before rendered
clopidogrel, on day 1 before associated varenicline, and on 14 day after associated
varenicline. Clopidogrel effect will be tested by measuring platelet phosphorylated-
VASP expressed as a platelet reactivity index (PRI). All patients were followed 6
months and they were documented smoking ceased rates, concomitant medication and
adverse events.JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CResults: The statistic comparison of the baseline data at admission in two groups
showed no signiﬁcant differences. In the conventional therapy group, PRI was
80.085.60%, 55.2114.87% and 43.0113.59% respectively at the three time. In
varenicline group, PRI was 79.945.18%, 53.7414.47% and 42.1811.27%
respectively at the three time. There was no signiﬁcant difference between the two
groups. The comparison of smoking ceased rates of two groups after 6 months: The
smoking cessation rate was 64.91% in the varenicline group. The smoking cessation
rate was 34.48%. The smoking cessation rate of the varenicline group was higher than
the control group (P<0.010). The data of eGFR were similar in the 2 groups. The
adverse events in varenicline group were higher than in conventional therapy group.
However, there was no signiﬁcant difference between the 2 groups. The serious
adverse events were identical between the 2 groups.
Conclusions: The rate of smoking cessation of varenicline was signiﬁcantly improved
in patients with CAD in periprocedure of PCI. Clopidogrel can be safely administrated
with varenicline without the need for dose adjustment.Cardiac Rehabilitation
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Relationship between exercise induced elevation of left ventricular ﬁlling
pressure estimated by E/e’ ratio and exercise intolerance in patients with atrial
ﬁbrillation
Chen Shaomin1,2, He Rong1,2, Feng Xinheng1,2, Li Zhaoping1,2, Chen Baoxia1,2,
Li Weihong1,2
1Department of Cardiology, Peking University Third Hospital, 2Key Laboratory of
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Objectives: Elevated left ventricular ﬁlling pressure (LVFP) is an important cause of
exercise intolerance in patients with atrial ﬁbrillation (AF). Exercise stress echocar-
diography could assess LVFP during exercise. The objective of this study was to
investigate the relationship between exercise induced elevation of LVFP estimated by
the ratio of early diastolic mitral inﬂow velocity (E) to early diastolic mitral annular
velocity (e’) and exercise capacity.
Methods: This study included 86 consecutive patients (48 men and 38 women;
mean age 64.69.2 years) with non-valvular AF and normal left ventricular systolic
function (left ventricular ejection fraction 50%). All patients underwent a symp-
tom-limited cardiopulmonary exercise test (CPET). Doppler echocardiography was
performed both at rest and immediately after exercise. Five consecutive measure-
ments of E and e’ were taken and averaged. E/e’ ratio was calculated. Elevated
LVFP was deﬁned as E/e’>9, and patients with elevated LVFP at rest were
excluded.
Results: Patients were classiﬁed into two groups according to LVFP estimated by E/e’
ratio after exercise: 64 (74.4%) with normal LVFP and 22 (25.6%) with elevated
LVFP after exercise. As compared with the patients with normal LVFP, the ones with
elevated LVFP after exercise had signiﬁcantly lower VO2 peak (22.02.6
vs 26.33.7 mL/min/kg, P<0.001), lower anaerobic thresbold (20.12.8 vs
25.74.0mL/min/kg, P<0.001), and shorter exercise time duration (6.20.9
vs 7.11.4min, P<0.001). Multivariate analysis identiﬁed 3 signiﬁcant variables that
are predicative of VO2 peak: age (r¼-0.412, P<0.001), gender (26.54.1 and
23.62.9mL/min/kg for male and female separately, P<0.001) and E /e’ after exercise
(r¼-0.607, P<0.001).
Conclusions: Elevated LVFP estimated by E/e’ ratio after exerceise is independently
associated with reduced exercise capacity. Exercise stress echocardiography could be
a useful diagnostic test for early diastolic dysfunction in AF patients.
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VO2/kg peak, VE/VCO2 nadir and VE/VCO2 slope of Cardiopulmonary Exercise
Testing Among Different Chinese CAD-patient Groups
Wang Yafei1, Liang Qi1, Zhang Guolin2, Liu Zhi2, Guo Lan2
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Objectives: To analyze variables (VO2/kg peak, VE/VCO2 nadir and VE/VCO2
slope) in cardiopulmonary exercise testing (CPET) among Chinese patients with
coronary artery disease (CAD) and to aid in developing more effective rehabilitation
programs.
Methods: This study was carried out in a cross-sectional observational way, and it
enrolled totally 38 CAD patients (30 have been treated by PCI and/or CABG) in
Guangdong General Hospital Cardiac Research Institute from November 1st, 2013 to
January 30th, 2014. After consent and clear of contraindications, every patient un-
derwent a CPET*, and patients were encouraged to exercise with maximal efforts. Aardiac Rehabilitation C207
set of variables (BP, HR, ECG, VO2, VCO2, VE/VCO2 and VE/VCO2 slope) was
obtained separately at rest, during exercise and in recovery phase in the test. All data
were computed with SPSS windows 17.0. Differences between two groups were
compared using two independent samples t-test, three groups or more than three
groups compared using ANOVA.
(*The indications for termination of testing include leg fatigue, chest pain, chest
distress, breathless, dizziness, severe cardiac arrhythmias and per patient’s request)
Results: 38 CAD patients (male gender, 73.68%; mean age, 60.2910.63 years,
PCI, 68.42%) were included, and there was no adverse cardiac event occurred
during the study. VO2/kg peak, VE/VCO2 nadir and VE/VCO2 slope were slightly
higher in male patients (male: 19.715.17 ml/kg/min, 26.934.422, 25.834.78;
female: 18.652.84 ml/kg/min, 24.43.31, 23.472.74, respectively). Although
statistically not signiﬁcant, the results showed variables in male patients had
slightly higher values. Furthermore, the ratio of male to female patients in our
small study group was 2.8 to 1. This might imply that males are more prone to
suffer CAD or the CAD male patients are more seeking medical treatment. The
difference between age groups was statistically insigniﬁcant. Elder patients (50y
and older, total 30) had slightly lower VO2/kg peak and higher VE/VCO2 nadir and
VE/VCO2 slope than younger adults (younger than 50y, 8 patients) (19.284.44
ml/kg/min, 26.44.12, 25.594.65 vs 20.015.71 ml/kg/min, 25.755.06,
23.573.35, respectively). No signiﬁcant difference was found among different
post-PCI duration groups.
Although statistically no signiﬁcant differences were found based on gender, age
and post-PCI duration, trends were seen that in CAD Chinese male patients the VE/
VCO2 nadir and VE/VCO2 slope were higher than female patients’ and the VE/VCO2
nadir and VE/VCO2 slope were increased as patients aged.
Conclusions: Older CAD Chinese male patients may have a poorer prognosis and
higher mortality than the younger female patients. The CPET offers a comprehensive
assessment tool for the rehabilitation program and should be widely performed in
clinical settings. Most CAD patients post PCI can initiate an exercise rehabilitation
program safely under the direction of doctors.Medical Rehabilitation of Cardiovascular Disease
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Effects of hypoxia training in rabbits with myocardial infarction
Wan Chunxiao, Wan Chuxniao
Rehabilitation Medicine Centre, Chinese PLA General Hospital
Objectives: To investigate the impact of hypoxia training in rabbits with myocardial
infarction(MI).
Methods: 18 adult male rabbits were randomly divided into three groups: group
SO(sham operated), group MI(myocardial infarction only) and group MI-HT(myo-
cardial infarction plus hypoxia training). MI was induced by left ventricular branch
ligation. Hypoxia training was performed in a hypobaric chamber at the altitude of
4000m, 1 h/day for 4 weeks. At the endpoints, echocardiography, capillary density
and VEGF level were measured.
Results: 4 weeks later, the plasma VEGF levels increased in Groups MI and MI-HT
signiﬁcantly, when compared to group SO. Group MI-HT decreased infarct size
(P<0.05) and increased capillary density (P<0.05) among all groups. Echocardiog-
raphy revealed an increased LV end-diastolic (LVEED) and end-systolic dimensions
(LVESD) but reduced LV ejection fraction (LVEF) in groups MI and MI-HT than in
group SO (P<0.01). Compared with group MI, group MI-HT improved LVEF and
decreased LVEDD and LVESD.
Conclusions: Hypoxia training may improve LV function and reduces LV remodel-
ing, and preserve the cardiac protection after MI insults.Traditional Rehabilitation of Cardiovascular Disease
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Danhong Injection Antagonizes Adriamycin-Induced Cardiotoxicity from
Oxidative Stress: Mechanism in vivo and in vitro
Jiang Xiaoqing, Wang Ting, Lv Bin, Li Pan, Gao Xiumei, Wang Xiaoying
Tianjin University of Traditional Chinese Medicine, Tianjin, China
Objectives: Adriamycin (ADM) is one of the most effective chemotherapeutic drugs
widely used for the treatment of various malignancies. Unfortunately, evidence sug-
gests that time and dose-dependent ADM therapy induces oxidative stress related
cardiotoxicity and heart failure which restricted clinical use of ADM. DanhongC208 JACC Vol 64/16/Suppl Cinjection (DHI), a traditional Chinese medicine with Danshen (Radix salviae mil-
tiorrhizae) and Honghua (Flos carthami), has been demonstrated to have the abilities
of reducing oxygen free radicals, protecting vascular endothelium, and anti-inﬂam-
matory effect. Thus, we performed a study to determine whether DHI could decrease
the ADM-induced injury in rats and endothelial cells, and investigated the potential
mechanisms.
Methods: Sprague-Dawley rats (28020 g) were randomly assigned to control, ADM
and ADM/DHI group (n¼6). Rats were administered through a single dose of 15
mg.kg1 (i.p.) in ADM and ADM/DHI groups. In ADM/DHI group, DHI at
0.067mL.kg1.d1 (i.p.) was given daily for 2 weeks, starting from 2 h after giving
ADM. Saline was used as control. Transthoracic echocardiography by Vevo 2100
ultrasound system was performed to evaluate left ventricular (LV) systolic and dia-
stolic function at baseline and 3, 7, 14 days after ADM administration. Besides, at the
end of 2 week, the animals were sacriﬁced to evaluate the vascular reactivity by
thoracic ring assay. Human umbilical vein endothelial cell line (Eahy926 cells) were
cultured in vitro. Methyl thiazolyltetrazolium (MTT) and lactate dehydrogenase
(LDH) were performed to determine cell viability. Xanthineoxidase method was
adopted to detect the activity of superoxide dismutases (SOD). To elucidate the effects
on apoptosis, AKT was detected by ELISA. FAS, anti-apoptotic gene Bcl-2 and pro-
apoptotic gene Bax were examined by quantitive real time PCR. Furthermore,
secretion of vascular endothelial growth factor (VEGF) was determined by ELISA.
Nitric oxide (NO) release was also been investigated.
Results: Clearly demonstrated time-dependent progression of heart dysfunction by
gradually decreased ejection fraction (EF), LV fractional shortening (FS), LV end-
systolic dimension (LVSD), LV end-diastolic volume (LVEDD), and the blood ﬂow
of LV outﬂow tract (LVOT) in ADM group. Meanwhile, the decreased cardiac
function could be obviously improved by DHI especially in peak vel of LVOT. Aortic
ring assay showed strongly reducing endothelium-dependent vasodilator responses by
ADM and a signiﬁcant increase in vasodilatation induced by Ach with DHI. DHI (10-4,
10-3, 10-2, 10-1 g/L) could improve cell viability against ADM injury (10-6 M) ac-
cording to MTT and LDH results. Furthermore, the release of SOD was signiﬁcantly
increased by DHI compare with ADM. RT-PCR showed decreased mRNA expression
of Bcl-2/Bax as well as enhanced expression of FAS in ADM group. Treatment with
DHI could upregulate Bcl-2/Bax and inhibit FAS. Besides, DHI could reverse ADM
decreased AKT levels. Notably, DHI also prevented VEGF expression but couldn’t
affect the suppressed NO generation by ADM.
Conclusions: This study indicated that DHI has protective effects against ADM-
induced cardiac dysfunction which might related to antagonize oxidative stress with
subsequent anti-apoptosis and improve endothelial function. The results may provide
a rational basis for Danhong injection to be an antidote to cardiac toxicity induced by
ADM in clinic.
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Clinical application of “treating different diseases with the same method” - Xuefu
Zhuyu Capsule (a traditional Chinese patent medicine) for blood stasis syndrome
Fu Shufei, Wang Yi, Ai Juqing, Abdulai Jawo Bah, Gao Xiumei
Tianjin University of Traditional Chinese Medicine
Objectives: Treatment based on syndrome differentiation has been one of the most
distinctive characteristics in the theory of traditional Chinese medicine (TCM). Based
on this theory, different diseases could be treated using the same method provided
they presented with the same syndrome. Xuefu Zhuyu Capsule as a prototype of
Chinese patent medicine has been used for many years in the treatment of blood stasis
syndrome. We tried to take this medicine as an example to introduce the connotation
of this theory according to evidence based medicine (EBM) methodology.
Objective: Take the clinical application of Xuefu Zhuyu Capsule for blood stasis
syndrome as an example to explain the TCM theory - treating different diseases with
the same method.
Methods: An extensive systemic literature review was done in January 2014. We
searched the following databases: PubMed, CENTRAL and Chinese full text data base
with the key words Xuefu Zhuyu Capsule (published before Jan 1st 2014). As Ran-
domized Controlled Clinical Trials (RCTs) were the golden standard to estimate an
intervention we just included the RCTs in this study. A Microsoft Access database
was established to collect the related data as subject information, intervention and
outcomes. We also evaluated and analyzed the methodological quality of each RCT to
validate their ﬁndings.
Results: 125 RCTs were included in this study. The ﬁrst one published in 1998. And
the methodological quality control of most trials was limited. Among the included
studies there was obvious clinical heterogeneity such as protopathy, duration, doses
and control intervention within the same disease. The inclusion criteria were not
uniform either. In these studies doses of Xuefu Zhuyu Capsule was used from 6 pills
to 18 pills per day. The shortest duration was 4 days and the longest reached to 1 year.
Most of the study did not mention the adverse reaction. Thus, meta-analysis was not
suitable for such studies that had so much heterogeneity. We just did some descriptive
analysis. In this study, more than 20 kinds of diseases with the syndrome of blood
stasis in the ﬁelds of internal medicine, gynaecology, orthopedics, dermatology and
otorhinolaryngology were treated by Xuefu Zhuyu Capsule. Studies of coronary heart
disease occupied the ﬁrst place. The treatment was effective in most of the diseases
with statistically signiﬁcant difference between test and control groups. But the pool
quality control of the included studies seriously affected the promotion and application
of the research results.j October 16–19, 2014 j GW-ICC Abstracts/Cardiac Rehabilitation
